Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
+$0.10 today
- Market cap
- $107.33M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
Volume 0.53M
Average 0.15M
FHTX Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Foghorn Therapeutics Inc.NASDAQ: FHTX
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue dips below year-ago levels
Q1 FY2026 revenue of $3.27M fell 45.1% year over year, behind the +20.1% change in trailing-twelve-month revenue. Sequentially, it fell 64.7% from the prior quarter. Over 3 fiscal years it compounded at +17.1% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $95.94M (+210.4%) for the fiscal year ending Dec 2026, a step up from the +36.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.27M-64.7% QoQ
- Last fiscal yearDec 2025
- $30.91M+36.8% YoY
- LTMMar 2026
- $28.22M+20.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -45.1% | -9.9% | +35.2 pp |
| 1 year | +36.8% | +210.4% | +173.6 pp |
| 3-year CAGR | +17.1% | -36.3% | -53.4 pp |
| 5-year CAGR | +21.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 30.91M USD
- Year-over-year change
- +36.8%
- 4-year CAGR
- +120.0%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.91M | +36.8% |
| FY2024 | 2024-12-31 | 22.6M | -33.8% |
| FY2023 | 2023-12-31 | 34.16M | +77.6% |
| FY2022 | 2022-12-31 | 19.23M | +1357.8% |
| FY2021 | 2021-12-31 | 1.32M | — |
Revenue vs competitors
How FHTX compares with its peers on the latest reported figures
- FHTX's LTM Mar 2026 revenue of $28.22M is the 5th highest of the 11 companies compared; the peer median is $9.8M.
- Its year-over-year change of +20.1% is the 2nd highest of 7, against a peer median of -29.5%.
- Over three fiscal years its annual growth of +17.1% compares with a peer median of -7.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $217.78M | +8.2% | -5.3% | |
| LTM Mar 2026 | $71.1M | +121.1% | — | |
| LTM Mar 2026 | $69.21M | +7.4% | -8.8% | |
| LTM Mar 2026 | $45.35M | -66.4% | -31.1% | |
| LTM Mar 2026 | $28.22M | +20.1% | +17.1% | |
| LTM Mar 2026 | $13.86M | — | — | |
| LTM Mar 2026 | $5.74M | -96.7% | — | |
| LTM Mar 2026 | $2.02M | -74.0% | +9.2% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | — | — |
| LTM Mar 2026 | $0 | — | — | |
ZURAZura Bio Limited | LTM Mar 2026 | $0 | — | — |
| Peer median (excluding FHTX) | $9.8M | -29.5% | -7.1% | |
Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.32M | 19.23M | 34.16M | 22.6M | 30.91M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.33M |
| Gross Profit | 1.32M | 19.23M | 34.16M | 22.6M | 27.58M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 89.2% |
| Research & Development | 80.33M | 105.62M | 109.69M | 94.53M | 85.47M |
| Selling, General & Admin | 21.73M | 30.75M | 32.37M | 28.36M | 27.55M |
| Operating Expenses | 102.05M | 136.37M | 142.06M | 125.29M | 109.68M |
| Depreciation & Amortization | 3.23M | 3.32M | 3.45M | 3.12M | 3.33M |
| EBITDA | (96.19M) | (105.56M) | (90.75M) | (97.17M) | (70.95M) |
| EBITDA Margin | -7292.4% | -549.0% | -265.7% | -429.9% | -229.5% |
| Operating Income | (100.73M) | (117.14M) | (107.91M) | (102.68M) | (82.11M) |
| Operating Margin | -7637.1% | -609.2% | -315.9% | -454.3% | -265.6% |
| Interest Income | 59K | 5.68M | 10.88M | 11.9M | 8.75M |
| Interest Expense | 1.91M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (586K) | 8.26M | 13.71M | 16.06M | 7.82M |
| Income Before Tax | (101.32M) | (108.88M) | (94.2M) | (86.62M) | (74.28M) |
| Pre-Tax Margin | -7681.6% | -566.3% | -275.8% | -383.2% | -240.3% |
| Income Tax Expense | 0 | 0 | 4.23M | 0 | 0 |
| Net Income | (101.32M) | (108.88M) | (98.43M) | (86.62M) | (74.28M) |
| Net Margin | -7681.6% | -566.3% | -288.2% | -383.2% | -240.3% |
| EPS (Basic) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| EPS (Diluted) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| Weighted Avg Shares | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
| Weighted Avg Shares (Diluted) | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Intrinsic Alpha fair value
Locked
Current Price
$1.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.